TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22077535
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of the Post-Concussion Scale
Study: 18754005
Drug: Delta 9-tetrahydrocannabinol
Normalized name: delta 9-tetrahydrocannabinol acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta 9-tetrahydrocannabinol (THC) inhalation
Study: 14695462
Drug: Warfarin (anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (anticoagulation intensity with INR > or = 1.5)
Study: 14695462
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 1.5-1.9)
Study: 14695462
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR > or = 2.0)
Study: 9385884
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rt-PA intravenous bolus followed by 80 mg i.v. infusion over 60 min (regimen A)
Study: 9385884
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg rt-PA over 90 min (C)
Study: 9385884
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rt-PA over 90 min (D)
Study: 26582883
Drug: rHPIV‐1/84/del 170/942A
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHPIV‐1/84/del 170/942A vaccine
Study: 23732788
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of propofol by a university‐degreed anesthesia registered nurse based on BIS values (Group 1)
Study: 23732788
Drug: Usual scheme
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual scheme of intravenous sedation with midazolam and fentanyl administered by the endoscopic team (Group 0)
Study: 16979998
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) prophylaxis (300 mg/d for patients >35 kg and 5 mg/kg/d for patients <35 kg) with Pyridoxine 50 mg/d for 1 year
Study: 14663472
Drug: Selenium-vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenium-vitamin E supplement for at least 6 months
Study: 14663472
Drug: No selenium-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No selenium-vitamin E supplement
Study: 14663472
Drug: Selenium-vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenium-vitamin E supplements
Study: 9773927
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: omeprazole 20 mg once daily for 2 weeks, amoxicillin 500 mg thrice daily, metronidazole 250 mg thrice daily, roxithromycin 150 mg twice daily for 1 week
Study: 9773927
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: same antibiotic treatment as group 1 for 1 week, plus omeprazole treatment for 2 weeks
Study: 8143059
Drug: Lysine-aspirin inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine-aspirin inhalation
Study: 3146893
Drug: Demonstration dose
Normalized name: OCTREOTIDE SA DEMONSTRATION KIT INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demonstration dose of sublingual nitroglycerin administered during the office visit
Study: 3146893
Drug: No demonstration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No demonstration dose (control group)
Study: 3146893
Drug: Demonstration dose
Normalized name: OCTREOTIDE SA DEMONSTRATION KIT INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demonstration dose of sublingual nitroglycerin
Study: 2884229
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment designed to achieve and maintain near-normal glucose levels (n = 18)
Study: 2884229
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 15)
Study: 2884229
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with stimulated C-peptide levels greater than 0.2 pmol/mL
Study: 31647147
Drug: EPA-enriched supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-enriched supplement
Study: 23703730
Drug: Web-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based acceptance and commitment therapy (ACT) intervention (WebQuit.org)
Study: 21499934
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100% oxygen for 50 minutes (Oxy50)
Study: 21499934
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100% oxygen followed by a 30-minute period after inhalation (After)
Study: 21499934
Drug: Before inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before inhalation of pure oxygen (Before)
Study: 21499934
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of air (Control group) for 20 minutes (Oxy20)
Study: 19459553
Drug: Bupivacaine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (500 mg) loaded microspheres
Study: 19459553
Drug: Bupivacaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (100 mg) and Ropivacaine (150 mg)
Study: 15302718
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) methylprednisolone (160 mg single dose)
Study: 15302718
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (8-day tapering of total 160 mg)
Study: 11451713
Drug: Dietary supplements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements, either alone or in combination with hormonal treatment
Study: 1117460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-fluorouracil (5-FU), methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine
Study: 26476489
Drug: lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium plus optimized personalized treatment (OPT)
Study: 26476489
Drug: optimized personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimized personalized treatment (OPT) without lithium
Study: 23503546
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch application followed by oral levodopa/benserazide, 100/25 mg
Study: 23503546
Drug: Nicotine and
Normalized name: lovastatin and nicotinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine and cotinine at 0.1 μmol/L
Study: 19339089
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with a standard trivalent inactivated influenza vaccine
Study: 9628086
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (1.3 micrograms/kg)
Study: 6989171
Drug: 1 alpha‐OHD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha‐OHD3 (1 microgram/day) + 2.5 g CaCO3
Study: 26424587
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg melatonin
Study: 26424587
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg melatonin (in women with sleep disturbances)
Study: 26424587
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin (in women with sleep disturbances)
Study: 24384420
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol sulfate and budesonide administered by inhalation twice a day for 7 days with Heliox
Study: 18612885
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (8 sessions)
Study: 18612885
Drug: Twelve-step treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve-step treatment (8 sessions)
Study: 12117401
Drug: Early-phase trials
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-phase trials for drug/device development
Study: 10721069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (epileptics with comparable clinical characteristics and treatment)
Study: 8628336
Drug: Polyprenoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyprenoic acid (600 mg daily)
Study: 21556366
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m²
Study: 21556366
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m²
Study: 7965263
Drug: Losartan 5
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 5 mg
Study: 7965263
Drug: Losartan 10
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 10 mg
Study: 7965263
Drug: Losartan 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 75 mg
Study: 7815703
Drug: Midazolam 0
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0 mg
Study: 8694203
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg
Study: 3758361
Drug: Intra-operative radiotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative radiotherapy (IOR) with doses of 28 to 35 Gy using electron beams
Study: 27644589
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus prompt laser treatment
Study: 27644589
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus deferred laser treatment
Study: 27644589
Drug: Ranibizumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab ± laser therapy
Study: 16723360
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid and/or immunosuppressive treatment
Study: 15319022
Drug: Olanzapine (1.25-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (1.25-2.5 mg/day starting dose, titrated to a mean of 14.5 mg/day by trial end)
Study: 15319022
Drug: Olanzapine (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (treatment group)
Study: 11148857
Drug: Tilidine/naloxone solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone solution (25 mg, 50 mg, 100 mg)
Study: 11148857
Drug: Tilidine/naloxone solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone solution (4 x 50 mg tilidine)
Study: 11148857
Drug: Tilidine/naloxone retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone retard tablets (50 mg, 100 mg, 200 mg tilidine/tablet)
Study: 9489119
Drug: Talc slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc slurry (5 g in 50 mL saline)
Study: 9489119
Drug: Bleomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (1 mg/kg in 50 mL saline)
Study: 8405501
Drug: Enoxaparin (ENX)
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (ENX) 4200 anti factor Xa IU once daily
Study: 8405501
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 7500 IU twice daily
Study: 3543577
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin-DHE
Study: 18568185
Drug: Low-dose indapamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indapamide (1.5 mg sustained release daily) with added perindopril
Study: 12435173
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (Aranesp) at doses < 1.5 microg/kg
Study: 12435173
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (Aranesp) at doses 1.5 to 2.25 microg/kg
Study: 12435173
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (Aranesp) at doses > 2.25 microg/kg
Study: 1826911
Drug: Isradipine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5, 5, 7.5, or 10 mg BID)
Study: 25808577
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy plus repeated botulinum toxin A (BoNT‐A/OT)
Study: 22970914
Drug: bFGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF treatment (direct application of bFGF drops in the clinic and repeated daily by the patient, n = 53)
Study: 22970914
Drug: bFGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF treatment (n = 53)
Study: 19176965
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 3,000 mg daily
Study: 15560807
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and metronidazole (400 mg t.i.d. for 10 days)
Study: 15560807
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and weekly professional supragingival plaque removal for three months (PC)
Study: 11159875
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg PRU
Study: 11159875
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg PRU
Study: 29654645
Drug: Testosterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (100 mg testosterone enanthate weekly for 7 weeks)
Study: 26657900
Drug: Split-Dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-Dose Group (SDG) - low-volume 2-L polyethylene glycol (PEG)-ascorbate solution in a 'split-dose' regimen
Study: 26657900
Drug: Day-Before Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-Before Group (DBG) - traditional 'full-dose, day-before' regimen
Study: 26657900
Drug: Split-Dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-Dose Group (SDG)
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A, n = 27)
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells 3 to 7 days after PCI (group B, n = 26)
Study: 26021558
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 25) - saline infusion performed immediately after emergency PCI
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells 7 to 30 days after PCI (group C, n = 26)
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A)
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells 3 to 7 days after PCI (group B)
Study: 26021558
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells 7 to 30 days after PCI (group C)
Study: 11239222
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg single dose)
Study: 9727725
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 600 mg per day
Study: 9727725
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 1600 mg per day
Study: 9727725
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unchanged medication)
Study: 21750157
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (hGH), 20 μg/kg/day
Study: 29871262
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and radiotherapy
Study: 29871262
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and chemotherapy plus adjuvant chemotherapy
Study: 23256145
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk intake (≥237 mL/d or 1 serving/d)
Study: 8348110
Drug: Nabumetone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1,000 mg once daily)
Study: 3789368
Drug: Buccal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal morphine 10 mg tablets
Study: 3789368
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate 13.5 mg
Study: 27447721
Drug: Sugar-free beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free beverage (250 mL per day) for 18 months
Study: 24332142
Drug: Full prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full prescription coverage with adherence (proportion of days covered ≥80%) to statin, β-blocker, or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Study: 22418773
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg once daily (QD)
Study: 22418773
Drug: Neratinib 120
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 120 mg twice daily (BID)
Study: 11929644
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg ethinyl estradiol + 2 mg dienogest (30 EE/DNG)
Study: 11929644
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg ethinyl estradiol + 2 mg dienogest (20 EE/DNG)
Study: 11929644
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg ethinyl estradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Study: 8588965
Drug: H1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 and H2-receptor-blocking agents in standard dosages preoperatively (Antihistamine group)
Study: 8588965
Drug: No histamine-receptor-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: No histamine-receptor-blocking agents (Control group)
Study: 28681626
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (100, 200, 400, 600, 800 mcg)
Study: 28681626
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (400, 600, 800 mcg)
Study: 28681626
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (600, 800 mcg)
Study: 23439692
Drug: Weekly reminder
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminder calls and homework assignments
Study: 12775969
Drug: Treprostinil infusion
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treprostinil infusion
Study: 16451393
Drug: Subcutaneous desferrioxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous desferrioxamine (DF)
Study: 2068599
Drug: ZDV (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV (experimental anti-HIV drug)
Study: 6340975
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms salbutamol 4-hourly
Study: 6340975
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms salbutamol 2-hourly
Study: 20626053
Drug: Control (tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tape treatment only)
Study: 12517329
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low-dose dopamine (3 microg/kg/min)
Study: 12517329
Drug: Furosemide 5
Normalized name: furosemide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 5 mg/hr infusion
Study: 31796061
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment according to the protocol for tobacco cessation by the Madrid Regional Health Service
Study: 25092528
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 8) performing exercises in a different order (compound exercises prior to isolation)
Study: 19220519
Drug: No educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: No educational intervention in Control County (CC)
Study: 17913754
Drug: 1 MAC
Normalized name: Macrodantin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 MAC sevoflurane administered via the ventilator for 15 min followed by a 15 min washout before CPB